Aakash Desai: The next frontier in immunotherapy Oral immune checkpoint inhibitors
Aakash Desai, Assistant Professor at UAB O’Neal Comprehensive Cancer Center, shared a post on LinkedIn:
“The next frontier in immunotherapy?
Oral immune checkpoint inhibitors (ICIs).
Early results from phase I trials of two oral PD-L1 inhibitors—ABSK043 and BPI-371153—show promising antitumor activity and manageable safety profiles in solid tumors, including NSCLC and MSI-high cancers.
Highlights:
• ABSK043: ORR of 19.6%, increasing to 41.7% in NSCLC with PD-L1 TPS ≥50%.
• BPI-371153: ORR of 23.5%, including a complete response in high PD-L1/TMB cases.
• Safety: No dose-limiting toxicities or peripheral neuropathy in either trial.
• Mechanism: Both agents dimerise PD-L1, inducing receptor down-regulation and immune activation.
Oral ICIs offer tangible benefits over antibodies: cost efficiency, better tumor penetration, and patient convenience.
While further studies are needed, these agents could redefine how we approach immunotherapy if efficacy aligns with antibody-based ICIs.
Exciting times for oncology research.”
More posts featuring Aakash Desai.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023